• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Usefulness of a healthcare database for epidemiological research in atrial fibrillation.
CONCLUSION: The data obtained in this study were comparable with results obtained in prospective cohort studies conducted in Japan. PMID: 28027833 [PubMed - as supplied by publisher]
Source: Journal of Cardiology - December 23, 2016 Category: Cardiology Authors: Koretsune Y, Yamashita T, Yasaka M, Oda E, Matsubayashi D, Ota K, Kobayashi M, Matsushita Y, Kaburagi J, Ibusuki K, Takita A, Iwashita M, Yamaguchi T Tags: J Cardiol Source Type: research

A Prospective, Randomized, Open-Label Study to Evaluate Two Management Strategies for Gastrointestinal Symptoms in Patients Newly on Treatment with Dabigatran
ConclusionThe majority of patients enrolled either did not experience GIS at all, or their GIS resolved using either one individually, or a combination of the two strategies described.Trial registrationhttp://www.ClinicalTrials.gov identifier: NCT01493557.
Source: Cardiology and Therapy - October 4, 2016 Category: Cardiology Source Type: research

Establishing Therapeutic Equivalence of Complex Pharmaceuticals: The Case of Dabigatran
Publication date: Available online 5 June 2018 Source:Canadian Journal of Cardiology Author(s): Jeffrey Weitz, Karen M. Earl, Kori Leblanc, William Semchuk, Fakhreddin Jamali Dabigatran is widely used for stroke prevention in atrial fibrillation. Dabigatran is no longer patent protected in Canada and 2 generic formulations were recently approved by Health Canada. Branded dabigatran utilizes a complex formulation to maintain the acidic microenvironment required for maximal absorption. Consequently, food does not influence its bioavailability and the efficacy and safety of dabigatran are similar with or without concomitant ...
Source: Canadian Journal of Cardiology - June 6, 2018 Category: Cardiology Source Type: research

Impact of proton pump inhibitors on mortality and severe esophageal injury after catheter ablation for atrial fibrillation: a nationwide retrospective study using propensity score matching
AbstractStudies on the protective effects of proton pump inhibitors (PPIs) on mortality and severe esophageal injury after catheter ablation for atrial fibrillation are lacking. However, some reports have recommended use of PPIs for prophylaxis against esophageal injury. We investigated the effects of PPIs on mortality and severe esophageal injury after ablation. We retrospectively extracted data for adult in-patients who received catheter ablation with a diagnosis of atrial fibrillation from July 2010 to March 2018. The patients were divided into two groups: with PPI (PPI group) and without PPI (non-PPI group) administrat...
Source: Heart and Vessels - April 30, 2021 Category: Cardiology Source Type: research

Influence of proton pump inhibitors on blood dabigatran concentrations in Japanese patients with non-valvular atrial fibrillation
Conclusions PPI administration significantly decreased the trough and peak DCs in patients with NVAF. Therefore, when prescribing PPIs for patients with NVAF in a clinical setting, the possibility that the bioavailability of dabigatran may decrease should be considered.
Source: Journal of Arrhythmia - October 13, 2017 Category: Cardiology Source Type: research

Oesophageal injury following magnetically guided single-catheter ablation for atrial fibrillation: insights from the MAGNA-AF registry
ConclusionMagnetically guided CA for AF with careful energy titration at the posterior LA wall and no oesophageal temperature monitoring is not associated with an increased incidence of oesophageal thermal injury. The routine use of periprocedural TOE may cause a low rate of mechanical oesophageal lesions but reliably prevents major complications like transient ischaemic attack, stroke, or cardiac tamponade. An observed high prevalence of upper digestive system inflammation (63%) may further support the recommendation for a routine post-interventional treatment with a proton-pump-inhibitor.
Source: Europace - May 1, 2018 Category: Cardiology Source Type: research

Bioequivalence of a Newly Developed Dabigatran Etexilate Tablet Versus the Commercial Capsule and Impact of Rabeprazole-Induced Elevated Gastric pH on Exposure in Healthy Subjects
ConclusionThe DE tablet demonstrated BE to the capsule; however, at high gastric pH, BA of the tablet was reduced by approximately 70%, which may lead to reduced efficacy. Data indicate the importance of examining not only BE under standard conditions, but relative BA at elevated gastric pH. Such investigations may avoid the reduced BA at elevated pH that is quite common in the target population (the elderly and/or patients treated with gastric-acid modifying co-medications), and therefore reduce treatment failure with DE.Registration: ClinicalTrials.gov identifier numbers: NCT03070171, and NCT03143166
Source: American Journal of Cardiovascular Drugs - October 29, 2019 Category: Cardiology Source Type: research

Impact of Rabeprazole on APO-Dabigatran Exposure in Healthy Volunteers
CONCLUSIONS: When APO-dabigatran is administered with rabeprazole, the exposure to dabigatran is reduced by about 30%, which is similar to the level observed with Pradaxa when it was co-administered with a proton pump inhibitor. However, the finding that one-third of participants had a > 50% reduction in exposure is concerning, and it highlights the need for caution in patients who have, or are at risk of, reduced gastric acidity.PMID:36700178 | PMC:PMC9869351 | DOI:10.1016/j.cjco.2022.09.006
Source: Atherosclerosis - January 26, 2023 Category: Cardiology Authors: Noel Chan Matt Wheeler Vinai Bhagirath Jacqueline Bosch Jutta Heinrich-Nols Debbie Sloane Joanne van Ryn Linda Jefferies Jacqueline Wilkinson Qilong Yi John Eikelboom Source Type: research